期刊名称：EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Expert Opinion on Drug Metabolism & Toxicology ranks #63 of 216 in the Pharmacology & Pharmacy category and #112 of 276 in the Biochemistry and Molecular Biology category in the 2008 ISI Journal Citation Reports.
Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
- Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data
- Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.
Indexing
Science Citation Index Expandedâ„? Biochemistry & Biophysics Citation Index, Chemical Abstracts (CODEN: EODMBQ), EMBASE/Excerpta, Medica, Index Medicus/Medline
Instructions to Authors
Instructions for authors can be found at the links below:
To submit a manuscript click here.
For full details of our editorial policies, including NIH-funded papers, please refer to our policy document and resources for authors.
The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Drug Metabolism & Toxicology. However, suggestions for article topics (and potential authors) are welcome, subject to final approval by the Editors and Editorial Board. If you are interested in preparing an article, please contact the Commissioning Editor with your proposal and an outline.
Peer review
All manuscripts are subject to confidential and anonymous (double-blinded) peer review by at least two independent referees. Comments remain confidential and are shared only with the corresponding author or submitting party. For our peer review guidelines, please click here.
Editorial Board
Commissioning Editor: Joris Roulleau
Production Editor: Sumayya Patel
Drug Evaluations Editor: Elizabeth Knowles
Marion Walter Anders - University of Rochester Medical Centre, Rochester, NY, USA
John Cashman - Human BioMolecular Research Institute, San Diego, CA, USA
Gert Fricker - University of Heidelberg, Heidelberg, Germany
Graham Lappin - Xceleron Ltd., York, England, UK
Geert Mannens - Johnson & Johnson Pharmaceutical R&D, Beerse, Belgium
John Miners - Flinders University, Adelaide, Australia
Olavi Pelkonen - University of Oulu, Oulu, Finland
Italo Poggesi - GlaxoSmithKline, Verona, Italy
Thomayant Prueksaritanont - Merck Research Laboratories, West Point, PA, USA
Adrian Ray - Gilead Sciences Inc., Foster City, CA, USA
Thomas Rushmore - Merck Research Laboratories, West Point, PA, USA
Jack Uetrecht - University of Toronto, Toronto, Ontario, Canada
Luis Valerio - FDA/CDER, Silver Spring, MD, USA
Hong Wan - AstraZeneca R&D, Mölndal, Sweden
|
